Monsanto: Anderson must uproot Bayer’s perennial problem - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

Monsanto: Anderson must uproot Bayer’s perennial problem

New chief needs to signal to investors whether a restructuring is likely

Bayer’s 2018 acquisition of US crop science company Monsanto is the takeover that just keeps on taking. This week’s €2.5bn impairment charge adds to already extensive financial damage. It will reinvigorate activist demands for a break-up.

Bayer paid $65bn for Monsanto assets that included a glyphosate weedkiller called Roundup. Management initially underestimated the high cost of an accompanying health scare, as managements typically do. Allegations that Roundup is carcinogenic have prompted numerous lawsuits.

Bayer trades at a depressed enterprise valuation of about 7 times forward ebitda. Change may now be in the air. Werner Baumann, the chief executive responsible for the Monsanto purchase, has stepped aside after a long period of poor share price performance. Replacement Bill Anderson started last month. As a former Roche executive, his expertise is drugs, not weedkillers.

A couple of things look odd about the impairment. First, it is relatively small, given that Bayer has about €39bn of goodwill on its balance sheet, more than half of which derives from the Monsanto acquisition. Second, Bayer blames a weak glyphosate market, which might be a temporary phenomenon, for the writedown. About 60 per cent of world sales are generic products, most of which are made in China.

Anderson will hopefully substitute signal for noise when he presents earnings on August 8. He should signal whether a restructuring is likely. Activists Inclusive Capital and Bluebell have called for this. They favour a spinout of the crop science unit, a business that troubles environmental, social and governance investors.

That would make sense. Even at 10 times next year’s ebitda, a sixth cheaper than rivals FMC and Corteva, Bayer’s crop science unit should be worth about €60bn, 2024 Visible Alpha estimates imply — albeit undiscounted for a long tail of legal claims. Compare that with the group’s total enterprise value of €86bn.

Bayer has argued that cash flow from crop science and its consumer health unit help fund its growing pharmaceuticals pipeline. But Bayer’s persistently low multiple against agrochemical and pharma peers underscores the need for change.

Anderson wishes to boost pharma, for example, by removing centralised research budgeting. But that could take years to lift the group’s low valuation. Like all incoming bosses, he has a brief window to cut loose a problem division. He should exploit it.

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

对话Otter.ai的梁松:我们可以从会议和对话中获取有价值的数据

这家会议转录初创公司的联合创始人认为,我们甚至可以用虚拟形象代替自己进行工作互动。

朔尔茨迎来自己的“拜登时刻”

德国总理受到党内压力,要求其效仿美国总统拜登退出竞选。

欧盟极右翼党团在气候和高层任命问题上获得更多支持

欧洲议会中右翼议员正越来越多地与极右翼联手瓦解该集团的绿色议程,并推动更严格的移民限制措施。

毛利人对新西兰后阿德恩时代的民粹主义转向感到愤怒

卢克森的保守党政府推翻了前总理的许多进步政策。

Lex专栏:英伟达令人炫目的增长与每个人都息息相关

这家芯片巨头的盈利对美国股票投资者来说是一件大事,这不仅仅是因为其3.6万亿美元的市值。

欧洲比以往任何时候都更需要企业增长冠军

欧洲正在急切地寻找企业增长冠军,FT-Statista按长期收入增长对欧洲企业进行的首次排名展示了这方面的可能性。
设置字号×
最小
较小
默认
较大
最大
分享×